



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 22, 2009

# Androclus Therapeutics

[View the current Androclus Therapeutics Page on BioPortfolio.com](http://www.bioportfolio.com/bioprofile/18472-Androclus+Therapeutics.html)  
(<http://www.bioportfolio.com/bioprofile/18472-Androclus+Therapeutics.html>)

## Contact Details:

**4204 Sorrento Valley Boulevard, suite a  
San Diego  
California  
92121  
United States of America**

Tel: 858 909 0020  
Fax: 858 909 0021  
Email: [investors@androclus.com](mailto:investors@androclus.com)

Androclus Therapeutics is a clinical-stage biotechnology company developing first-in-class selective therapeutics for the treatment of autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and inflammatory bowel disease (IBD), based on a proprietary epitope-specific immunotherapy technology platform. The breakthrough technology platform has a potential of producing the next generation of safer, orally administered therapeutics. Currently available biologics for the treatment of autoimmune diseases are typically associated with long-term safety risks due to broad immunosuppression, have an inconvenient parenteral route of administration and high cost. Androclus' drug candidates are designed to provide improved treatment options to patients by offering increased selectivity in targeting chronic autoimmune inflammation without broad immunosuppression, an improved tolerability and safety profile, more convenient oral route of administration, and lower cost of goods.

## Press Releases on Androclus Therapeutics:

[Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal](#)

20th November, 2009

Cornerstone Therapeutics Inc.

*CARY, N.C., Nov. 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products*

[Reportlinker Adds Global Self Monitoring Blood Glucose Market \(SMBG\): Increasing Adoption to Drive Growth](#)

20th November, 2009

Reportlinker

NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to

[Cell Therapeutics Wins Federal Appeal to Pursue \\$22.8 Million Claim Against The Lash Group](#)

20th November, 2009

Cell Therapeutics, Inc.

SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled

[Monogram Energy, Inc. Acquires Triad Therapeutics, Inc.](#)

19th November, 2009

Monogram Energy, Inc.

FAIRFIELD, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Monogram Energy, Inc. ("Monogram") (Pink Sheets: MGRN) announced today that it had completed the acquisition of Triad Therapeutics, Inc. (

[Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals's siRNA Drugs In Multiple Fully Enrolled Clinical Trials](#)

19th November, 2009

Quark Pharmaceuticals, Inc.

-- Pfizer Inc., which licenses PF-4523655 from Quark, has completed enrollment in a Phase 2 study of PF-4523655 in patients with diabetic macular edema (DME). PF-4523655 is

## BioNews Results for Androclus Therapeutics



- [Ark Therapeutics Group plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new PR inside: Nov 16 2009 5:01AM Matching: therapeutics](#)
- [Astex Announces Strategic Drug Discovery Alliance with GlaxoSmithKline PipelineReview: Nov 15 2009 8:48PM Matching: therapeutics](#)
- [EKR Therapeutics to Present at the Lazard Capital Markets 2009 Healthcare Conference Pharma Live: Nov 14 2009 10:40PM Matching: therapeutics](#)
- [Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002 KOTA Territory News: Nov 14 2009 11:05PM Matching: therapeutics](#)
- [Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002 Medical News Today: Nov 14 2009 10:16AM Matching: therapeutics](#)

- [Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002](#)  
*KSLA: Nov 14 2009 7:29AM Matching: therapeutics*
- [Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002](#)  
*Pharmacy Choice: Nov 14 2009 12:59AM Matching: therapeutics*
- [Aileron Therapeutics Collaborators Publish In Vivo Research in Nature Showing Stapled Peptides Achieve the Fir](#)  
*Pharma Live: Nov 14 2009 12:33AM Matching: therapeutics*
- [Nile Therapeutics Reports 2009 Third Quarter Financial Results](#)  
*Freshnews.com: Nov 13 2009 12:29AM Matching: therapeutics*
- [Echo Therapeutics Announces \\$3 Million Financing](#)  
*Pharmacy Choice: Nov 13 2009 10:19PM Matching: therapeutics*
- [Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002](#)  
*Freshnews.com: Nov 13 2009 5:25PM Matching: therapeutics*
- [Nile Therapeutics Reports 2009 Third Quarter Financial Results](#)  
*Genetic Engineering News: Nov 13 2009 7:28AM Matching: therapeutics*
- [Five Prime Therapeutics, Inc. to Present at Lazard Capital Markets 6th Annual Healthcare Conference](#)  
*Pharma Live: Nov 13 2009 7:06AM Matching: therapeutics*
- [Astex Therapeutics signs drug discovery agreement with GlaxoSmith...](#)  
*Zibb: Nov 13 2009 8:12PM Matching: therapeutics*
- [Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002](#)  
*TickerTech.com: Nov 13 2009 8:09PM Matching: therapeutics*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical

practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

